Year: 2020
Type: review
Study design: Observational Study
Abstract: OBJECTIVES: Information on the recently COVID-19-associated pulmonary aspergillosis (CAPA) entity is scarce. We describe eight CAPA patients, compare them to colonised ICU patients with coronavirus disease 2019 (COVID-19), and review the published literature from Western countries. METHODS: Prospective study (March to May, 2020) that included all COVID-19 patients admitted to a tertiary hospital. Modified AspICU and European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria were used. RESULTS: COVID-19-associated pulmonary aspergillosis was diagnosed in eight patients (3.3% of 239 ICU patients), mostly affected non-immunocompromised patients (75%) with severe acute respiratory distress syndrome (ARDS) receiving corticosteroids. Diagnosis was established after a median of 15 days under mechanical ventilation. Bronchoalveolar lavage was performed in two patients with positive Aspergillus fumigatus cultures and galactomannan (GM) index. Serum GM was positive in 4/8 (50%). Thoracic CT scan findings fulfilled EORTC/MSG criteria in one case. Isavuconazole was used in 4/8 cases. CAPA-related mortality was 100% (8/8). Compared with colonised patients, CAPA subjects were administered tocilizumab more often (100% vs. 40%, p = .04), underwent longer courses of antibacterial therapy (13 vs. 5 days, p = .008), and had a higher all-cause mortality (100% vs. 40%, p = .04). We reviewed 96 similar cases from recent publications: 59 probable CAPA (also putative according modified AspICU), 56 putative cases and 13 colonisations according AspICU algorithm; according EORTC/MSG six proven and two probable. Overall, mortality in the reviewed series was 56.3%. CONCLUSIONS: COVID-19-associated pulmonary aspergillosis must be considered a serious and potentially life-threatening complication in patients with severe COVID-19 receiving immunosuppressive treatment.
Source: Mycoses
DOI: 10.1111/myc.13213
Authors: Marina Machado(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing), Maricela Valerio(Conceptualization, Methodology, Writing – review & editing), Ana Álvarez‐Uría(Investigation, Methodology), María Olmedo(Investigation), Cristina Veintimilla(Investigation), Belén Padilla(Investigation), Sofía De la Villa(Investigation), Jesús Guinea, Pilar Escribano(Investigation, Methodology), María Jesús Ruiz‐Serrano(Methodology, Resources), Elena Reigadas(Investigation, Resources), Roberto Alonso(Investigation, Resources), José Eugenio Guerrero(Resources), Javier Hortal(Resources), Emilio Bouza(Supervision, Writing – review & editing), Patricia Muñoz(Conceptualization, Supervision, Writing – review & editing), the COVID‐19 Study Group
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Keywords: COVID-19-associated pulmonary aspergillosis, invasive pulmonary aspergillosis, COVID-19 pandemic, Aspergillus fumigatus, corticosteroid immunosuppression, acute respiratory distress syndrome, mechanical ventilation, galactomannan, isavuconazole, tocilizumab, intensive care unit patients, mortality, EORTC/MSG criteria
Open Access status: bronze
OpenAlex ID: W3099019571
